Zevra Therapeutics (ZVRA) Expected to Post Earnings on Tuesday

Zevra Therapeutics (NASDAQ:ZVRA) is projected to release its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to announce earnings of $0.14 per share and revenue of $37.08 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:30 PM ET.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.25 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.14. Zevra Therapeutics had a net margin of 42.82% and a return on equity of 54.54%. The firm had revenue of $39.66 million for the quarter, compared to analyst estimates of $33.88 million. On average, analysts expect Zevra Therapeutics to post $0.72 EPS for the current fiscal year and $0.84 EPS for the next fiscal year.

Zevra Therapeutics Trading Down 2.9%

Shares of NASDAQ ZVRA opened at $9.53 on Tuesday. The stock has a market cap of $565.89 million, a PE ratio of 6.21 and a beta of 0.98. Zevra Therapeutics has a 12-month low of $8.01 and a 12-month high of $15.03. The company has a 50-day moving average of $11.30 and a 200 day moving average of $10.70.

Insider Buying and Selling

In other Zevra Therapeutics news, Director Corey Watton sold 12,300 shares of Zevra Therapeutics stock in a transaction on Monday, August 10th. The stock was sold at an average price of $11.25, for a total value of $138,375.00. Following the sale, the director owned 1,800 shares in the company, valued at $20,250. The trade was a 87.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Neil F. Mcfarlane sold 20,000 shares of Zevra Therapeutics stock in a transaction on Monday, October 12th. The shares were sold at an average price of $11.25, for a total value of $225,000.00. Following the completion of the sale, the chief executive officer owned 417,225 shares in the company, valued at $4,693,781.25. This represents a 4.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 3.70% of the company’s stock.

Wall Street Analyst Weigh In

ZVRA has been the subject of several recent research reports. William Blair raised Zevra Therapeutics to a “strong-buy” rating in a report on Wednesday, September 23rd. Weiss Ratings reissued a “hold (c)” rating on shares of Zevra Therapeutics in a research note on Wednesday, August 19th. Guggenheim dropped their target price on Zevra Therapeutics from $24.00 to $23.00 and set a “buy” rating for the company in a report on Friday, August 7th. UBS Group reaffirmed a “buy” rating on shares of Zevra Therapeutics in a research note on Thursday, August 20th. Finally, Citizens Jmp boosted their price target on shares of Zevra Therapeutics from $25.00 to $28.00 and gave the company a “market outperform” rating in a research report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $27.14.

About Zevra Therapeutics

Zevra Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with significant unmet medical needs. The company combines traditional drug development with data science and patient-focused research to advance therapies for diseases that may have limited treatment options.

Zevra’s lead commercial product is MIPLYFFA (arimoclomol), which is approved in the United States for the treatment of neurological manifestations of Niemann-Pick disease type C in adults and children aged 2 years and older, in combination with miglustat.